FMC Announced Support of Ukrainian Farmers

Feb 24, 2023

FMC announced they will be supporting Ukrainian farmers by donating three per cent of sales revenue through the Cultivating Freedom program, according to a release. The program will support agricultural business that have been impacted in de-occupied regions.

With safety as one of their core values, FMC’s donation of three per cent of 2023 sales revenue will assist with demining efforts in impacted regions of the Ukraine. Through FMC product purchases, Ukrainian farmers in freed territories as well as the reconstruction of the Ukraine will be supported.

“Our commitment to Ukraine and our support to local farmers goes back several decades. Today we are happy to keep building these relationships by bringing our latest technologies to the agricultural sector, and to directly help farmers safely access their fields, thus enabling them to work again,” said Sebastià Pons, FMC vice president and president, FMC Europe, Middle East, Africa.

Operations and business in Russia were discontinued by FMC at the beginning of the Russian invasion of Ukraine.

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.